AIxCrypto Launches AIxC Hub with Over 200,000 Registered Users
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: Newsfilter
- Surge in User Engagement: Since its launch on January 7, AIxC Hub has attracted over 200,000 registered wallet addresses, reflecting strong early adoption that is expected to drive long-term growth and ecosystem expansion.
- Competitive Season Launch: The inaugural season, S1 Arena, focuses on market simulation, allowing users to earn points by making directional predictions on the C10 Index, with a zero-capital risk design that lowers entry barriers and enhances understanding of RWA trading logic.
- Social Media Interaction: Within the first 48 hours of launch, AIxC-related content generated over 3 million social media impressions, showcasing significant market impact and user engagement, which is anticipated to further enhance brand visibility.
- Global Market Expansion: AIxCrypto has partnered with over 160 KOLs, reaching an audience of over 8 million, establishing early community presence in Vietnam, Korea, and China, with plans for expansion into Brazil and Europe to strengthen its global market footprint.
Analyst Views on AIXC
About AIXC
AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
